Parkinson's Disease Exercise TMS PET Study

Exercise and Parkinson's Disease: The Basis for Motor and Cognitive Benefits

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02265900

Enrollment

Registered

2014-10-16

Start date

2014-11-30

Completion date

2020-03-12

Last updated

2021-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

Positron Emission Tomography, Dopamine, Parkinson's Disease

Brief summary

The therapeutic effects of exercise in Parkinson's disease (PD) are commonly reported, however the mechanisms are unknown. The purpose of this study is to investigate the potential mechanisms of exercise in the brain for the treatment of PD.

Detailed description

Positron Emission Tomography will be used to measure dopamine neuron density, endogenous dopamine release and neuroimflammation. We will also use functional magnetic resonance imaging (fMRI) to measure brain activity. Assessments will be conducted before and after a 12-week exercise intervention and 3-year follow-up. Participants will be randomly allocated into either an aerobic or a stretching intervention. Clinical measures of motor function, cognition and mood will also be assessed.

Interventions

OTHERExercise

One type of exercise

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

40 Years to 80 Years

Healthy volunteers

Inclusion criteria

Diagnosed with Parkinson's Disease, Exercise less than 3x per week.

Exclusion criteria

. Describe which potential participants will be excluded from participation, and list the criteria for their exclusion. 1. atypical Parkinson syndrome (progressive supranuclear palsy, multiple system atrophy, drug-induced etc.); 2. significant osteoporosis or arthritis; 3. other neurological disease/complications (e.g. myopathy, stroke, brain lesion, MS); 4. self-reports claustrophobia; 5. history of cancer within 5 years of study participation; 6. high dose of radiation from other procedures within the year; 7. not able to tolerate being off PD medication for up to 24 hours; 8. a female subject who is breast-feeding or pregnant. 9. Subjects who regularly use anti-inflammatories (only excluded for PBR scans).

Design outcomes

Primary

Measure	Time frame
Change in Dopamine release measured by RAC PET	4 months

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026